secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vitro Biopharma, Inc. (—)
CIK:        0000793171
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001493152-24-020410
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vitro BioPharma issues $375K convertible notes at 20% OID and warrants in private placement
--------------------------------------------------------------------------------

- Aggregate principal $375,000; purchase price $300,000 (20% original issue discount); interest 20% per annum.
- Notes mature May 16, 2024, extendable to Aug 16, 2024; secured by all company assets.
- Warrants exercisable for 5 years; conversion/exercise terms tied to Liquidity Event or $95M fully-diluted valuation.
- Issued pursuant to prior securities purchase agreement (Nov 16, 2023); exempt under Section 4(a)(2) of Securities Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer